Becton, Dickinson and Company (NYSE:BDX) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,402 shares of the medical instruments supplier's stock after selling 6,293 shares during the period. PNC Financial Services Group Inc. owned approximately 0.06% of Becton, Dickinson and Company worth $42,289,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Oak Hill Wealth Advisors LLC increased its position in shares of Becton, Dickinson and Company by 206.7% during the fourth quarter. Oak Hill Wealth Advisors LLC now owns 6,809 shares of the medical instruments supplier's stock worth $1,545,000 after acquiring an additional 13,189 shares during the period. Edgestream Partners L.P. purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $1,255,000. West Family Investments Inc. lifted its stake in Becton, Dickinson and Company by 8.9% in the fourth quarter. West Family Investments Inc. now owns 1,175 shares of the medical instruments supplier's stock worth $267,000 after acquiring an additional 96 shares during the last quarter. Ashton Thomas Private Wealth LLC grew its holdings in Becton, Dickinson and Company by 117.8% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 3,214 shares of the medical instruments supplier's stock worth $729,000 after acquiring an additional 1,738 shares in the last quarter. Finally, Callan Family Office LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $299,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

BDX has been the subject of several analyst reports. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Barclays upped their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, March 5th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Buy" and an average price target of $278.29.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company's stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares of the company's stock, valued at $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,423 shares of company stock valued at $1,239,780 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.24 on Wednesday, reaching $225.16. The stock had a trading volume of 533,309 shares, compared to its average volume of 1,506,275. The stock has a market cap of $64.65 billion, a P/E ratio of 37.52, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The business's 50-day moving average price is $232.96 and its 200 day moving average price is $232.57. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.